thought call
boost lack biz-dev specif ideal pt
guidanc consensu think today reaction reflect lack clariti
regard plan repatri sizeabl cash reservesalthough
may admittedli seek greater impact tax reform follow abbvi
earn result last week believ today move overreact remain ow
rais pt although deal seem best path forward
exceed single-digit top-lin growth think afford patient
inde near-term growth driversinclud xeljanz prevnar eliquislook
remain strong well xtandi ibranc re-acceler top-lin
guidanc impli growth midpoint also like progress made
repriorit pipelin provid number catalyst
throughout includ potenti strategi i/o lung manag
allud number binari event need resolv plan
solidifi continu like risk/reward profil share
near-term catalyst may offer upsid among key catalyst expect
upcom readout bavencio nsclc renal cell carcinoma
inlyta well tripl manag expect file
talazoparib brca mbc xtandi nmcrpc prosper lorlatinib mutat
nsclc dacomitinib egfr mutat nsclc glasdegib aml
phase develop start next-gener inhibitor
atop dermat well difficil vaccin
model chang weve rais sale sale
given impact tax reform repres improv
bp estim adjust dilut ep
respect
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight better balanc sheet access
expect let find growth asset return
excess capit sharehold make
better risk/reward commerci regulatori
pipelin success still crucial risk
taken asset lead sustain growth
 primarili frame tax consider
cost synergi
better expect uptak prevnar ibranc
xtandi offset price pressur essenti
coupl pipelin success oncolog
success deploy capit toward could
result upsid forecast
faster eros essenti due price
pressur along lower growth innov could
result weaker top line growth failur deploy
capit pipelin asset could cloud
long-term outlook result share stay
valuat per share price target reflect blend averag discount
cash flow analysi impli intrins valu per share base wacc
termin growth rate price-to-earnings analysi assum
share maintain current year multipl forward earn suggest per
prior target base blend averag price-to-earnings base
compar analysi assum multipl expans appli current year
multipl forward year earn impli valu per share dcf
assum wacc termin growth impli intrins valu per
million except per share itemspriorcurr chg amort incom attribut common item net ep ep outstand outstand analysiscurrentcurr chgchg bp gross changecurrentcurr chgchg incom incom million except per share itemspriorcurr chg amort incom attribut common item net ep ep outstand outstand analysiscurrentcurr chgchg bp gross changecurrentcurr chgchg incom incom barclay inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
